> I no longer own a single share. LAR concerns and the impending Liraglutide have scared me off, along with a lofty valuation. I'm curious to know if you have any thoughts on Liraglutide vs. Byetta LAR.<
Liraglutide—as well as NVO itself—appears to be formidable competition. Given the valuation, I cannot fault your decision to take profits on AMLN. Regards, Dew
Market Data 
Markets 
AI
